



A History of Diagnostic Contribution to Antimicrobial Stewardship

1989

Clearview® Strep A; a 5 minute rapid test to diagnose Strep A pharyngitis and prevent the use of unnecessary antibiotics for patients with viral pharyngitis.

NycoCard™ CRP Visual Test; is launched, helping doctors to significantly reduce antibiotic prescribing for lower respiratory tract infections in primary care.

1994

The world's first **Legionella ELISA** test for the presumptive diagnosis, treatment and management of Legionnaires' disease.

1998

The world's first rapid lateral flow **Legionella urine antigen test** aiding the rapid diagnosis and appropriate therapy for Legionnaires' disease within 15 minutes.

1999

The unique rapid **urinary antigen test for Streptococcus pneumoniae;** aiding in the diagnosis of pneumococcal pneumonia and appropriate narrow spectrum antibiotics.

2000

The quantitative **NycoCard™ CRP Single Test** and **NycoCard™ Reader** are launched.

2002

Alere BinaxNOW® Influenza A&B tests; allowing avoidance of unnecessary antibiotics and prudent use of antivirals within 15 minutes.

2003

Alere BinaxNOW® RSV; a 15 minute test assisting the physician to withhold unnecessary antibiotics.



2005

The fully automated **Alere Afinion™ CRP** point-of-care immunoassay is launched on the **Alere Afinion™ Analyzer**. This 4 minute test makes it even easier to discriminate serious illness such as pneumonia from often self-limiting illness like acute bronchitis and other RTI in a primary care setting.

2009

C. DIFF QUIK CHEK COMPLETE® (TechLab®, Inc.); a unique rapid test for the detection of *Clostridium difficile*. This Healthcare Associated Infection (HAI) is often a consequence of poor Antimicrobial Stewardship (AMS).

2010

The **Alere™ PBP2a Culture Colony Test;** Aids in identifying MRSA from bacterial isolates identified as *Staphylococcus aureus* in 6 minutes. This can be up to 24 hours sooner than traditional methods.

2012


SHIGA TOXIN QUIK CHEK™ (TechLab®, Inc.); a unique test for the detection of Vero-toxigenic (VTEC) *E. coli* directly from a stool sample. Antibiotic treatment for VTEC can increase the risk of secondary complications.

2013

Alere™ i Influenza A & B, the first CLIA-waived point of care rapid molecular test aiding the diagnosis of influenza, enabling better treatment management and AMS.

2015

Alere™ i Strep A; The speed and accuracy of the **Alere™ i Strep A** test empowers healthcare professionals to initiate the right treatment in an actionable time-frame.




2015

The **Alere™ PBP2a SA Culture Colony Test** Aids in identifying MRSA from bacterial isolates identified as *Staphylococcus aureus* in 6 minutes. This can be up to 24 hours sooner than traditional methods. Product has been optimized with improvements to procedure and room temp storage.

2016

Alere™ i RSV; The first molecular test that can be used at the point-of-care to detect RSV in 13 minutes or less.



**TEST
TARGET
TREAT™**